40.46
[1]. Francesca Tentori, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 01 Jan 7;10(1):98-109.
[]. Frank Gotch, et al. Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration. Blood Purif. 010;9():163-76.
[3]. Jason Gee, et al. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D in patients with clinically localized prostate cancer and high grade pin. Prostate. 013 Jun;73(9):970-8.
[4]. Jun H Choi, et al. Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats. J Card Fail. 011 Dec;17(1):101-8.
[]. Neil Kumar, et al. Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations. Am J Nephrol. 009;9():71-8.
P64-P70-P330-P40-P01
811
![]()
![]()